- ASCO® 2024
- Yale Cancer Answers
- ASH CME Series
- Smilow Shares with Primary Care
- Grand Rounds
- Head and Neck
- Gynecologic
- Benign Hematology
- Breast
- GI
- Lung
- GU
- Hematologic Oncology
- Brain
- Cancer Screening
- DEI (Diversity, Equity and Inclusion)
- 2021 ASH Highlights
- General Events
- Events
Playback speed
10 seconds
Post-Hoc Analyses of Phase 3 ARCHES Trial: OS in Patients With mHSPC Who Received Prior ADT and Reached Low PSA Levels Treated Further With Enzalutamide
By
Yale Cancer Center
FEATURING
Daniel Petrylak
By
Yale Cancer Center
FEATURING
Daniel Petrylak
665 views
December 16, 2022
Comments 0
Login to view comments.
Click here to Login
GU